Committee introduces RS 32318 addressing 340B contract‑pharmacy access after debate

The House Health & Welfare Committee introduced RS 32318, a proposal from Representative Jordan Redmond concerning Idaho’s approach to the federal 340B drug discount program.

Representative Redmond said the RS seeks to bring accountability to drug manufacturers that participate in 340B and to restore or expand contract‑pharmacy access for entities that lost it in 2020. "Many of these people lost the ability to be 340B contract pharmacies and so I think that this will just get them back," Representative McCann said in support, calling the RS a replacement rather than an expansion. Representative Redmond emphasized the program is federally regulated and said it involves discounts from manufacturers rather than tax dollars: "there's no tax dollars involved in this," he said.

Committee debate: Representative Kaler moved a substitute motion to send RS 32318 back to the sponsor, arguing the expansion was excessive and suggesting the committee should first give the earlier bill fuller consideration. Supporters, including Representative McCann, said stakeholders had worked extensively and characterized the RS as restoring access. Representative Burgoyne asked whether federal money is involved; Representative Redmond replied that the program is federally regulated but that the discounted drug sales are not tax dollars.

Votes and outcome: The committee conducted a roll call on a motion (the transcript records a roll call that reads, in part, as verbal tallies) and recorded, in the transcript, "Roll call shows 3 A's, 11 A's, motion fails." The record later states "RS 32,318 is introduced." The transcript shows subsequent hand votes and confirmations; the committee ultimately recorded that RS 32,318 was introduced.

Why it matters: The 340B program governs manufacturer discounts to eligible safety‑net providers and contract pharmacies; changes at the state level or actions affecting contract pharmacies can affect drug access and the operations of clinics, hospitals and pharmacies that rely on discounted medicines to serve patients.

Next steps: The RS has been introduced and would follow the usual drafting or printing process before being scheduled for further hearings or referral to additional committees. The committee did not record a detailed fiscal analysis or statutory text during the hearing.

Limitations: Committee members explicitly discussed that federal regulation governs the 340B program and that state action has limits; no specific statutory language was read into the record and no fiscal figures were provided in the hearing transcript.